Connecticut § 21a-70j Disclosures re legend drugs.

Connecticut Statutes

§ 21a-70j — Disclosures re legend drugs.

Connecticut § 21a-70j

Title 21aConsumer Protection

Ch. 417General Provisions. Pure Food and Drugs

This text of Connecticut § 21a-70j (Disclosures re legend drugs.) is published on Counsel Stack Legal Research, covering Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Conn. Gen. Stat. § 21a-70j (2026).

Text

Each pharmaceutical marketing firm that employs or compensates a pharmaceutical representative who is engaged in marketing, promoting or providing information regarding a legend drug for human use in this state shall ensure that such pharmaceutical representative discloses, in writing, to a prescribing practitioner or pharmacist, each time such pharmaceutical representative makes contact with the prescribing practitioner or pharmacist:

(1)The list price of a legend drug when such pharmaceutical representative provides information concerning the legend drug to such prescribing practitioner or pharmacist based on the dose and quantity of such legend drug as described in the medication package insert; and (2) Information on the variation efficacy of the legend drug marketed to different raci

Free access — add to your briefcase to read the full text and ask questions with AI

Each pharmaceutical marketing firm that employs or compensates a pharmaceutical representative who is engaged in marketing, promoting or providing information regarding a legend drug for human use in this state shall ensure that such pharmaceutical representative discloses, in writing, to a prescribing practitioner or pharmacist, each time such pharmaceutical representative makes contact with the prescribing practitioner or pharmacist: (1) The list price of a legend drug when such pharmaceutical representative provides information concerning the legend drug to such prescribing practitioner or pharmacist based on the dose and quantity of such legend drug as described in the medication package insert; and (2) Information on the variation efficacy of the legend drug marketed to different racial and ethnic groups, if such information is available.

Legislative History

(P.A. 23-171, S. 5; P.A. 24-80, S. 4.) History: P.A. 24-80 substantially amended provisions including by transferring duties from pharmaceutical representative to pharmaceutical marketing firm, effective May 30, 2024.